The gamechanger for renal cancer screening, diagnosis and prognosis
We have developed innovative molecular diagnostic kits on liquid biopsy, along with machine learning software for the analysis and accurate interpretation of results, enabling SCREENING, DIAGNOSIS, and PROGNOSIS of RENAL CANCER
MiRECLE®
(MicroRNA REnal Cancer Liquid Evaluation)
We analyze patented panels of circulating microRNAs through its 3 MiRECLE® (MicroRNA REnal Cancer Liquid Evaluation) kits:
MiRECLE-S for screening
MiRECLE-D for diagnosis
MiRECLE-P for prognosis
BIOREK technology is based on the use of Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR).
MiRECLE kits will be available firstly for research use only (RUO) and then also as in vitro diagnostic kits (IVD-KITs).
MiRECLE kits are highly sensitive and specific, minimally invasive, requiring only a simple blood sample, and easy and quick to perform, with clinical results in 72 hours.